Table 3.
Secondary outcomes of recurrence of CDI within 6 months and length of initial in hospital stay
| Placebo (n=74) |
Rifaximin (n=77) |
Intervention effect (95% CI) |
||
| Recurrence of CDI within 6 months | ||||
| Data available | 61 | 66 | ||
| No recurrence | 41 (67.2%) | 52 (78.8%) | Risk difference | Risk ratio |
| Recurrence | 20 (32.8%) | 14 (21.2%) | −11.6% (−27.0% to 3.7%) | 0.65 (0.36, 1.16) |
| Risk difference | Risk ratio | |||
| Hospitalisation for recurrence | 8 (13.1%) | 9 (13.6%) | 0.5% (−11.1% to 12.0%) | 1.04 (0.43 to 2.52) |
| Total number of recurrences | ||||
| 1 | 17 | 12 | ||
| 2 | 1 | 1 | ||
| 3 | 2 | 1 | ||
| Length of in hospital stay following start of treatment | ||||
| Inpatient at start of treatment | 25 | 29 | ||
| Discharged on the same day as start of treatment | 4 | 2 | ||
| Withdrew consent on the same day as randomisation | 0 | 1 | ||
| HR | ||||
| Median length of stay (95% CI) | 21 (4 to 29) | 15 (6 to 40) | 0.94 (0.52 to 1.71) | |
| n | 21 | 26 | ||
Number of participants with 6 months outcome data available is used as the denominator for recurrence and hospitalisation for recurrence.
Risk difference/risk ratio and 95% CIs calculated using generalised estimating equations (to account for hospital) using the Binomial family.
Median length of stay based on Kaplan Meier survival estimates.
Unadjusted HR for length of in hospital stay is reported as the shared frailty model used to account for stratification by site did not converge.
CDI, Clostridium difficile infection.